Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.59x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HAE stock price at premium vs NYT $102.95 current versus $66.01 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NYT's multiple
Implied fair value · at HAE's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · NYT FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.59x
Capital structure 95% equity / 5% debt · EV / Revenue 3.82x · EV / EBITDA 19.47x
NYT carries the larger enterprise value at $10.78B against $5.68B; NYT trades on the lower EV / Revenue multiple (3.82x vs 4.26x); NYT on the lower EV / EBITDA (19.47x vs 21.59x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
THE NEW YORK TIMES COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.56x
0.26x
Net debt / EBITDA
Leverage against operating earnings
3.80x
-0.22x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$642.16M
Total debt
Interest-bearing obligations outstanding
$1.24B
$520.69M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.